Citi lowered the firm’s price target on Novo Nordisk (NVO) to DKK 340 from DKK 400 and keeps a Neutral rating on the shares. The firm cites the company’s weaker than expected guidance for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk CEO: I’m confident from a supply perspective for the Wegovy pill
- Novo Nordisk Stock Nosedives 18% on Eli Lilly’s Q4 Beat, 2026 Sales Outlook
- Novo Nordisk Details 2025 Pay, Leadership Shake-Up and Pipeline Progress in Latest Remuneration Report
- Balancing Solid 2025 Results Against Mounting 2026 Headwinds: Maintaining a Hold on Novo Nordisk
- These Are the Stocks Reporting Earnings Today – February 4, 2026